Avoid Mix-Ups With the New Antipsychotics Caplyta and Secuado

April 2020

Caplyta (kah-PLY-tah, lumateperone) and Secuado (seh-KWAH-doh, asenapine) will be two new atypical antipsychotics for schizophrenia.

Caplyta is a 42 mg oral capsule that's taken once daily.

Expect it to be saved for patients who don't respond to or can't tolerate lower-cost atypicals, such as olanzapine or risperidone.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Storage & Disposal Highlight Med Disposal Options for Patients
NSAIDs Look for Voltaren Arthritis Pain Gel on OTC Shelves
Practice Follow Best Practices for Billing Insulin Pens
Cholesterol Nexletol Will Be a New Add-On Med for High Cholesterol
Respiratory & Allergy Watch for Changes With Montelukast and Olopatadine Products
Inventory Management Use Strategies to Minimize Pharmacy Shrink
Med Safety Reduce the Risk of Mishaps Related to Knowledge, Action, or Memory
Antipsychotics Avoid Mix-Ups With the New Antipsychotics Caplyta and Secuado
Migraine Expect Fewer Rxs to Prevent Migraine in Kids